title: The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans.
abstract: The neurovascular unit provides a dynamic interface between the circulation and central nervous system. Disruption of neurovascular integrity occurs in numerous brain pathologies including neurotrauma and ischaemic stroke. Tissue plasminogen activator is a serine protease that converts plasminogen to plasmin, a protease that dissolves blood clots. Besides its role in fibrinolysis, tissue plasminogen activator is abundantly expressed in the brain where it mediates extracellular proteolysis. However, proteolytically active tissue plasminogen activator also promotes neurovascular disruption after ischaemic stroke; the molecular mechanisms of this process are still unclear. Tissue plasminogen activator is naturally inhibited by serine protease inhibitors (serpins): plasminogen activator inhibitor-1, neuroserpin or protease nexin-1 that results in the formation of serpin:protease complexes. Proteases and serpin:protease complexes are cleared through high-affinity binding to low-density lipoprotein receptors, but their binding to these receptors can also transmit extracellular signals across the plasma membrane. The matrix metalloproteinases are the second major proteolytic system in the mammalian brain, and like tissue plasminogen activators are pivotal to neurological function but can also degrade structures of the neurovascular unit after injury. Herein, we show that tissue plasminogen activator potentiates neurovascular damage in a dose-dependent manner in a mouse model of neurotrauma. Surprisingly, inhibition of activity following administration of plasminogen activator inhibitor-1 significantly increased cerebrovascular permeability. This led to our finding that formation of complexes between tissue plasminogen activator and plasminogen activator inhibitor-1 in the brain parenchyma facilitates post-traumatic cerebrovascular damage. We demonstrate that following trauma, the complex binds to low-density lipoprotein receptors, triggering the induction of matrix metalloproteinase-3. Accordingly, pharmacological inhibition of matrix metalloproteinase-3 attenuates neurovascular permeability and improves neurological function in injured mice. Our results are clinically relevant, because concentrations of tissue plasminogen activator: plasminogen activator inhibitor-1 complex and matrix metalloproteinase-3 are significantly elevated in cerebrospinal fluid of trauma patients and correlate with neurological outcome. In a separate study, we found that matrix metalloproteinase-3 and albumin, a marker of cerebrovascular damage, were significantly increased in brain tissue of patients with neurotrauma. Perturbation of neurovascular homeostasis causing oedema, inflammation and cell death is an important cause of acute and long-term neurological dysfunction after trauma. A role for the tissue plasminogen activator-matrix metalloproteinase axis in promoting neurovascular disruption after neurotrauma has not been described thus far. Targeting tissue plasminogen activator: plasminogen activator inhibitor-1 complex signalling or downstream matrix metalloproteinase-3 induction may provide viable therapeutic strategies to reduce cerebrovascular permeability after neurotrauma.
authors: Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria 3004, Australia.
authors: Maithili
authors: M
authors: Sashindranath
authors: Eunice
authors: E
authors: Sales
authors: Maria
authors: M
authors: Daglas
authors: Roxann
authors: R
authors: Freeman
authors: Andre L
authors: AL
authors: Samson
authors: Elisa J
authors: EJ
authors: Cops
authors: Simone
authors: S
authors: Beckham
authors: Adam
authors: A
authors: Galle
authors: Catriona
authors: C
authors: McLean
authors: Cristina
authors: C
authors: Morganti-Kossmann
authors: Jeffrey V
authors: JV
authors: Rosenfeld
authors: Rime
authors: R
authors: Madani
authors: Jean-Dominique
authors: JD
authors: Vassalli
authors: Enming J
authors: EJ
authors: Su
authors: Daniel A
authors: DA
authors: Lawrence
authors: Robert L
authors: RL
authors: Medcalf
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000418:Albumins / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000098:blood supply / Q000378:metabolism; D001930:Brain Injuries / Q000134:cerebrospinal fluid / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D002199:Capillary Permeability / Q000187:drug effects / Q000502:physiology*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007276:Injections, Intraventricular; D008297:Male; D061965:Matrix Metalloproteinase Inhibitors / Q000627:therapeutic use; D020782:Matrix Metalloproteinases / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000008:administration & dosage / Q000378:metabolism / Q000502:physiology*; D020127:Recovery of Function / Q000502:physiology; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*
chemical_list: D000418:Albumins; D061965:Matrix Metalloproteinase Inhibitors; D017395:Plasminogen Activator Inhibitor 1; D010959:Tissue Plasminogen Activator; D020782:Matrix Metalloproteinases